Wall Street Zen Downgrades Supernus Pharmaceuticals (NASDAQ:SUPN) to Hold

Wall Street Zen cut shares of Supernus Pharmaceuticals (NASDAQ:SUPN) from a buy rating to a hold rating in a research note published on Saturday morning.

Separately, Cantor Fitzgerald restated a “neutral” rating and issued a $36.00 price target on shares of Supernus Pharmaceuticals in a research report on Wednesday, February 26th.

Supernus Pharmaceuticals Stock Down 0.9%

Shares of Supernus Pharmaceuticals stock opened at $31.99 on Friday. Supernus Pharmaceuticals has a 12-month low of $25.55 and a 12-month high of $40.28. The firm has a market capitalization of $1.79 billion, a PE ratio of 28.82 and a beta of 0.71. The stock’s fifty day moving average is $32.15 and its 200-day moving average is $34.13.

Institutional Investors Weigh In On Supernus Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in SUPN. Raiffeisen Bank International AG bought a new position in Supernus Pharmaceuticals during the fourth quarter valued at approximately $25,000. Financial Management Professionals Inc. bought a new position in shares of Supernus Pharmaceuticals during the 1st quarter valued at $30,000. Versant Capital Management Inc raised its holdings in shares of Supernus Pharmaceuticals by 6,931.3% during the 1st quarter. Versant Capital Management Inc now owns 1,125 shares of the specialty pharmaceutical company’s stock valued at $37,000 after purchasing an additional 1,109 shares in the last quarter. Caitong International Asset Management Co. Ltd bought a new position in Supernus Pharmaceuticals during the first quarter valued at about $41,000. Finally, GF Fund Management CO. LTD. bought a new position in Supernus Pharmaceuticals during the fourth quarter valued at about $42,000.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.